Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04397510 · ClinicalTrials.gov registry record · Phase 4
Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury
A Phase 4 study, sponsored by Frederick Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT04397510 is a Phase 4 study that was terminated before completion, run by Frederick Health. The registered enrollment target is 13 participants.
The verdict
NCT04397510, a Phase 4 study, was terminated before completion, sponsored by Frederick Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
Randomized, placebo controlled study to determine if nebulized heparin may reduce the severity of lung injury caused by the novel coronavirus, also known as COVID-19
Interventions
- DRUG Heparin
- DRUG 0.9% Sodium-chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04397510
The ClinicalTrials.gov registry entry for NCT04397510 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Frederick Health, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Heparin is the first listed.
NCT04397510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04397510 about?
NCT04397510 is a clinical study titled "Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury". Randomized, placebo controlled study to determine if nebulized heparin may reduce the severity of lung injury caused by the novel coronavirus, also known as COVID-19
What is the current status of trial NCT04397510?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2020-06-01. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT04397510?
The interventions under investigation include: Heparin (DRUG), 0.9% Sodium-chloride (DRUG).
Who is sponsoring clinical trial NCT04397510?
This trial is sponsored by Frederick Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.